Stock Track | Apellis Pharmaceuticals Soars 9.62% Pre-Market on Revenue Growth Despite Q4 Loss

Stock Track

2025/02/28

Apellis Pharmaceuticals Inc. (APLS) stock soared 9.62% in the pre-market session on Friday, following the release of its fourth-quarter 2024 earnings report.

The biopharmaceutical company reported a net loss of $36.35 million or $0.29 per share for the quarter. However, the losses were offset by strong product revenue of $191.17 million, reflecting robust sales growth for the company's products.

Despite the net loss, investors reacted positively to the revenue growth, driving the stock higher in anticipation of continued momentum. Operating expenses remained high at $238.69 million, but the market seems to be focused on the top-line performance for now.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1155971265"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1155971265\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1155971265?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-28 20:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155971265","market":"hk","top_or_hot":-1,"title":"Stock Track | Apellis Pharmaceuticals Soars 9.62% Pre-Market on Revenue Growth Despite Q4 Loss","media":"Stock Track","content":"<p>Apellis Pharmaceuticals Inc. (APLS) stock soared 9.62% in the pre-market session on Friday, following the release of its fourth-quarter 2024 earnings report.</p>\n\n<p>The biopharmaceutical company reported a net loss of $36.35 million or $0.29 per share for the quarter. However, the losses were offset by strong product revenue of $191.17 million, reflecting robust sales growth for the company's products.</p>\n\n<p>Despite the net loss, investors reacted positively to the revenue growth, driving the stock higher in anticipation of continued momentum. Operating expenses remained high at $238.69 million, but the market seems to be focused on the top-line performance for now.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Apellis Pharmaceuticals Soars 9.62% Pre-Market on Revenue Growth Despite Q4 Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Apellis Pharmaceuticals Soars 9.62% Pre-Market on Revenue Growth Despite Q4 Loss\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-02-28 20:08</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Apellis Pharmaceuticals Inc. (APLS) stock soared 9.62% in the pre-market session on Friday, following the release of its fourth-quarter 2024 earnings report.</p>\n\n<p>The biopharmaceutical company reported a net loss of $36.35 million or $0.29 per share for the quarter. However, the losses were offset by strong product revenue of $191.17 million, reflecting robust sales growth for the company's products.</p>\n\n<p>Despite the net loss, investors reacted positively to the revenue growth, driving the stock higher in anticipation of continued momentum. Operating expenses remained high at $238.69 million, but the market seems to be focused on the top-line performance for now.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"APLS","symbol_name":"Apellis Pharmaceuticals Inc.","start_time":0,"source_url":"","article_id":"1155971265","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155971265","pubTimestamp":1740744499,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Apellis Pharmaceuticals Inc.  stock soared 9.62% in the pre-market session on Friday, following the release of its fourth-quarter 2024 earnings report.The biopharmaceutical company reported a net loss of $36.35 million or $0.29 per share for the quarter. However, the losses were offset by strong product revenue of $191.17 million, reflecting robust sales growth for the company's products.Despite the net loss, investors reacted positively to the revenue growth, driving the stock higher in anticip","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"APLS":"Apellis Pharmaceuticals Inc."},"translate_title":"尽管第四季度亏损，Apellis Pharmaceuticals仍因收入增长而盘前飙升9.62%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APLS":1},"content_text":"Apellis Pharmaceuticals Inc. (APLS) stock soared 9.62% in the pre-market session on Friday, following the release of its fourth-quarter 2024 earnings report.\nThe biopharmaceutical company reported a net loss of $36.35 million or $0.29 per share for the quarter. However, the losses were offset by strong product revenue of $191.17 million, reflecting robust sales growth for the company's products.\nDespite the net loss, investors reacted positively to the revenue growth, driving the stock higher in anticipation of continued momentum. Operating expenses remained high at $238.69 million, but the market seems to be focused on the top-line performance for now.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}